Exact Mass: 497.12325940000005
Exact Mass Matches: 497.12325940000005
Found 107 metabolites which its exact mass value is equals to given mass value 497.12325940000005
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
2-Methyl-1-hydroxypropyl-ThPP
2-Methyl-1-hydroxypropyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15976). It is the second to last step in the synthesis of isobutyryl-CoA and is converted from 3-methyl-2-oxobutanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(2-methylpropanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]]. [HMDB] 2-Methyl-1-hydroxypropyl-ThPP is an intermediate in valine, leucine and isoleucine degradation(KEGG ID C15976). It is the second to last step in the synthesis of isobutyryl-CoA and is converted from 3-methyl-2-oxobutanoate via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]. It is then converted to S-(2-methylpropanoyl)-dihydrolipoamide-E via the enzyme 2-oxoisovalerate dehydrogenase [EC:1.2.4.4]].
Tebipenem Pivoxil
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DH - Carbapenems D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C2140 - Adjuvant > C183118 - Beta-lactamase Inhibitor
Idarubicin
Idarubicin is only found in individuals that have used or taken this drug. It is an orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. [PubChem]Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors
(9S)-9-Acetyl-7-[(2R,4S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D004791 - Enzyme Inhibitors
Tebipenem pivoxil
Melphalan Flufenamide
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents > L01AA - Nitrogen mustard analogues D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
Nitrile,1-O-beta-D-glucopyranoside,penta-Ac-1,4-Dihydroxy-2-cyclopentene-1-carboxylic acid
C22H27NO12 (497.15331820000006)
Idarubicin
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01D - Cytotoxic antibiotics and related substances > L01DB - Anthracyclines and related substances C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C259 - Antineoplastic Antibiotic C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D004791 - Enzyme Inhibitors
Cys Cys Ser Trp
C20H27N5O6S2 (497.14026820000004)
Cys Cys Trp Ser
C20H27N5O6S2 (497.14026820000004)
Cys Asp Phe Asn
C20H27N5O8S (497.15802620000005)
Cys Asp Asn Phe
C20H27N5O8S (497.15802620000005)
Cys Phe Asp Asn
C20H27N5O8S (497.15802620000005)
Cys Phe Asn Asp
C20H27N5O8S (497.15802620000005)
Cys Met Met Asn
C17H31N5O6S3 (497.14363860000003)
Cys Met Asn Met
C17H31N5O6S3 (497.14363860000003)
Cys Asn Asp Phe
C20H27N5O8S (497.15802620000005)
Cys Asn Phe Asp
C20H27N5O8S (497.15802620000005)
Cys Asn Met Met
C17H31N5O6S3 (497.14363860000003)
Cys Ser Cys Trp
C20H27N5O6S2 (497.14026820000004)
Cys Ser Trp Cys
C20H27N5O6S2 (497.14026820000004)
Cys Trp Cys Ser
C20H27N5O6S2 (497.14026820000004)
Cys Trp Ser Cys
C20H27N5O6S2 (497.14026820000004)
Asp Cys Phe Asn
C20H27N5O8S (497.15802620000005)
Asp Cys Asn Phe
C20H27N5O8S (497.15802620000005)
Asp Phe Cys Asn
C20H27N5O8S (497.15802620000005)
Asp Phe Asn Cys
C20H27N5O8S (497.15802620000005)
Asp Asn Cys Phe
C20H27N5O8S (497.15802620000005)
Asp Asn Phe Cys
C20H27N5O8S (497.15802620000005)
Phe Cys Asp Asn
C20H27N5O8S (497.15802620000005)
Phe Cys Asn Asp
C20H27N5O8S (497.15802620000005)
Phe Asp Cys Asn
C20H27N5O8S (497.15802620000005)
Phe Asp Asn Cys
C20H27N5O8S (497.15802620000005)
Phe Asn Cys Asp
C20H27N5O8S (497.15802620000005)
Phe Asn Asp Cys
C20H27N5O8S (497.15802620000005)
Met Cys Met Asn
C17H31N5O6S3 (497.14363860000003)
Met Cys Asn Met
C17H31N5O6S3 (497.14363860000003)
Met Met Cys Asn
C17H31N5O6S3 (497.14363860000003)
Met Met Asn Cys
C17H31N5O6S3 (497.14363860000003)
Met Asn Cys Met
C17H31N5O6S3 (497.14363860000003)
Met Asn Met Cys
C17H31N5O6S3 (497.14363860000003)
Asn Cys Asp Phe
C20H27N5O8S (497.15802620000005)
Asn Cys Phe Asp
C20H27N5O8S (497.15802620000005)
Asn Cys Met Met
C17H31N5O6S3 (497.14363860000003)
Asn Asp Cys Phe
C20H27N5O8S (497.15802620000005)
Asn Asp Phe Cys
C20H27N5O8S (497.15802620000005)
Asn Phe Cys Asp
C20H27N5O8S (497.15802620000005)
Asn Phe Asp Cys
C20H27N5O8S (497.15802620000005)
Asn Met Cys Met
C17H31N5O6S3 (497.14363860000003)
Asn Met Met Cys
C17H31N5O6S3 (497.14363860000003)
Ser Cys Cys Trp
C20H27N5O6S2 (497.14026820000004)
Ser Cys Trp Cys
C20H27N5O6S2 (497.14026820000004)
Ser Trp Cys Cys
C20H27N5O6S2 (497.14026820000004)
Trp Cys Cys Ser
C20H27N5O6S2 (497.14026820000004)
Trp Cys Ser Cys
C20H27N5O6S2 (497.14026820000004)
Trp Ser Cys Cys
C20H27N5O6S2 (497.14026820000004)
Lenampicillin hydrochloride
C21H24ClN3O7S (497.10234240000005)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
2-Methyl-2-propanyl {3-[4-chloro-1-(phenylsulfonyl)-1H-pyrrolo[2, 3-b]pyridin-3-yl]benzyl}carbamate
C25H24ClN3O4S (497.1175974000001)
2-CHLORO-4-NITROPHENYL-β-D-CELLOBIOSIDE
C18H24ClNO13 (497.09361240000004)
2-(BIS(2-(2-(2-METHYL-5-NITRO-1H-IMIDAZOL-1-YL)ETHOXY)-2-OXOETHYL)AMINO)ACETIC ACID
C18H23N7O10 (497.15063380000004)
1-Isoamyl-2-methyl-3,3-dibenzyl-5-chloroindolium bromide
C28H33BrClN (497.1484748000001)
1,3-Thiazol-4-ylmethyl [(2S,3S,5S)-5-amino-3-hydroxy-1,6-diphenyl -2-hexanyl]carbamate dihydrochloride
2-chloro-4-nitrophenyl-beta-d-lactoside
C18H24ClNO13 (497.09361240000004)
Tributylmethylphosphonium bis(trifluoromethanesulfonyl)imide
C15H30F6NO4PS2 (497.1257982000001)
2-[[4-[bis[2-(acetyloxy)ethyl]amino]-2-methylphenyl]azo]benzothiazol-6-yl thiocyanate
Ertapenem Sodium
C22H24N3NaO7S (497.12325940000005)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
(7R,9R)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
4-[(2-hydroxy-3-nitrophenyl)-(5-methyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)methyl]-5-methyl-2-phenyl-1H-pyrazol-3-one
Melphalan Flufenamide
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents > L01AA - Nitrogen mustard analogues D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-4,6,9-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(2,3-dihydroxybenzoyl)amino] phosphate
C17H18N6O10P- (497.08219980000007)
L-gammaGlu-S-[[1,7-Dioxo-2,5,6-trimethyl-1H,7H-pyrazolo[1,2-a]pyrazole-3-yl]methyl]-L-Cys-Gly-OH
C20H27N5O8S (497.15802620000005)
(7S,9S)-9-acetyl-7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
1-[2,3-Bis(2-furanyl)-6-quinoxalinyl]-3-[4-(4-morpholinyl)phenyl]thiourea
C27H23N5O3S (497.15215280000007)
N-[1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-1-methyl-4-oxo-6-(pyrrolidin-1-ylsulfonyl)-1,4-dihydroquinoline-3-carboxamide
C25H27N3O6S (497.1620482000001)
3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl-[5-(4-bromophenyl)-7-(trifluoromethyl)-1,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]methanone
2-[4-[1-[1-[(4-Methylphenyl)sulfonylmethyl]-5-tetrazolyl]propyl]-1-piperazinyl]-1,3-benzothiazole
2-[(1R,3R,4aS,9aR)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2,2,2-trifluoroethyl)acetamide
2-[(1R,3R,4aS,9aR)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2,2,2-trifluoroethyl)acetamide
2-[(1R,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2,2,2-trifluoroethyl)acetamide
2-[(1S,3S,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2,2,2-trifluoroethyl)acetamide
2-[(1S,3R,4aR,9aS)-6-[[(2-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2,2,2-trifluoroethyl)acetamide
2-[(1R,3R,4aR,9aS)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2,2,2-trifluoroethyl)acetamide
2-[(1S,3S,4aS,9aR)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2,2,2-trifluoroethyl)acetamide
2-[(1S,3S,4aR,9aS)-6-[[(4-fluoroanilino)-oxomethyl]amino]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2,2,2-trifluoroethyl)acetamide
(2Z)-2-cyano-2-[(5Z)-5-[[4-(difluoromethoxy)-3-methoxyphenyl]methylidene]-3-(3-methoxypropyl)-4-oxo-1,3-thiazolidin-2-ylidene]-N-(2-methoxyethyl)acetamide
[(1S)-2-[2-[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]seleninyl-1H-imidazol-5-yl]-1-carboxyethyl]-trimethylazanium
(7R-cis)-9-Acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
2-Methyl-1-hydroxypropyl-TPP
The diphosphate of thiamine(1+), substituted at C-2 of the thiazole ring by a hydroxylated sec-butyl group.
(7R,9R)-9-acetyl-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
FAAH inhibitor 1
FAAH inhibitor 1 (Benzothiazole analog 3) is a potent fatty acid amide hydrolase (FAAH) inhibitor with an IC50 of 18±8 nM[1].
Lu AF27139
C21H19ClF3N5O2S (497.0900020000001)
Lu AF27139 is a potent, selective, and orally active antagonist of P2X7 receptor (IC50s of 12 and 2.4 nM for human and rat, Kis of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 has rodent-active and CNS-penetrant character. Lu AF27139 has the potential for the research of CNS diseases[1].